LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, announces that AdBIOPRO consortium, the Competence Center for Advanced BioProduction, at Royal Institute of Technology, Stockholm, Sweden, has had its official start on March 22, 2023. This program consists of 24 members of which 16 are companies representing large, medium, and small biopharma, bioreactor providers, upstream and downstream technology and media providers and 8 are academic groups. Cellevate is one of the technology providers for Upstream AAV (adeno-associated virus), lentivirus and cell therapy bioproduction. The Competence Centre funding lasts for five years, and the consortium is led by Dr. Véronique Chotteau at KTH in Stockholm, Sweden, a world recognized expert in the field of mammalian cell culture in biopharmaceutical industry and continuous bioprocessing in large scale biologics production.
The AdBIOPRO Centre, which is sponsored by VINNOVA and the consortium partners, aims to develop competitive technology for bioproduction and manufacturing of emerging potent therapeutic products such as recombinant viral vector, glycoproteins, and cell products. Furthermore, the goal is to facilitate new biopharmaceuticals to be produced more economically and more sustainably.
“We are excited to be part of AdBIOPRO as it is truly a fantastic initiative that provides both the framework and the opportunity to collaborate to develop the best innovative solutions for the ongoing revolution in biomanufacturing of cell and gene therapies. At the same time with the goal to increase productivity and improve sustainability, ultimately enabling these therapies to reach more patients”, says Laura Chirica, CEO Cellevate.
For more information, please contact:
Laura Chirica, PhD
Cellevate is a spin out from NanoLund – a world leading nanomaterial academic center. The company founded in 2014, develops and markets products based on a proprietary nanofiber-based platform – the Cellevat3d™ – a game-changing, green and sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of microcarriers with unparalleled surface area for cell growth, reproducibility and customization. Cellevat3d™ microcarriers products are designed for laboratory testing of cell lines as well as pilot and large-scale batch production of novel classes of biological therapies, including cell- and gene therapies and vaccines. Cellevat3d™ microcarriers have a commercial launch and sales start planned for 2024.
For more information, please visit www.cellevate.com.